Teda Biological (08189) announced its interim results, with a profit attributable to shareholders of 10.2083 million yuan, marking a year-on-year turnaround to profitability.
Teda Biotechnology (08189) announced its interim results for the six months ending June 30, 2026, with a revenue of 296 million yuan, an increase of 30.75% year-on-year; profit attributable to owners of the company was 10.2083 million yuan, compared to a loss of 6.4264 million yuan in the same period last year; earnings per share were 0.048 yuan.
Teda Biomedical (08189) announced its interim results for the six months ending June 30, 2026. The group achieved a revenue of 296 million yuan, a year-on-year increase of 30.75%; profit attributable to owners of the company was 10.2083 million yuan, compared to a loss of 6.4264 million yuan in the same period last year; earnings per share were 0.048 yuan.
Related Articles
MNSO (09896) invested $251,600 to buy back 107,600 shares on August 31.
NIO-SW (09866) delivered 35,836 vehicles in August, a year-on-year increase of 14.5%.
XPENG-W (09868) delivered a total of 39,107 new cars in August, a year-on-year increase of 4%.
MNSO (09896) invested $251,600 to buy back 107,600 shares on August 31.
NIO-SW (09866) delivered 35,836 vehicles in August, a year-on-year increase of 14.5%.
XPENG-W (09868) delivered a total of 39,107 new cars in August, a year-on-year increase of 4%.
RECOMMEND
